+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Cancer Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Cancer Drugs Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989947
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Drugs Market is projected to reach USD 188.72 Billion in 2026. It is expected to continue growing at a CAGR of 10.13%, reaching USD 338.29 Billion by 2032.

The cancer drugs market is being reshaped by rising cancer incidence, longer treatment duration, and rapid innovation across immuno-oncology, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, cell therapies, hormone therapy, chemotherapy, and supportive oncology care. According to the International Agency for Research on Cancer, the world recorded about 20 million new cancer cases and 9.7 million cancer deaths in 2022, underscoring sustained demand for effective oncology therapeutics.

Commercial momentum is increasingly linked to biomarker-driven treatment, real-world evidence, and accelerated regulatory pathways. Pharmaceutical leaders are prioritizing precision oncology pipelines, combination regimens, oral oncology drugs, biosimilars, and earlier-line indications to improve survival outcomes while addressing payer scrutiny around high-cost cancer medicines and equitable patient access.

Transformative Shifts in the Cancer Drug Landscape

The oncology landscape is moving from broad cytotoxic treatment toward personalized cancer therapy guided by genomic profiling, companion diagnostics, tumor-agnostic approvals, liquid biopsy, and measurable residual disease monitoring. Checkpoint inhibitors, kinase inhibitors, PARP inhibitors, bispecific antibodies, CAR-T therapies, radioligand therapies, and antibody-drug conjugates are expanding the cancer treatment arsenal and changing standards of care across solid tumors and hematologic malignancies.

At the same time, the market is becoming more evidence-intensive. Health technology assessment agencies, value-based reimbursement models, and oncology clinical pathways are increasing pressure on manufacturers to demonstrate overall survival, progression-free survival, durable response, quality-of-life improvement, safety, and cost-effectiveness in real-world populations.

Cumulative Impact of Artificial Intelligence in Oncology

Artificial intelligence is accelerating oncology drug discovery by improving target identification, protein modeling, compound screening, biomarker discovery, clinical trial matching, and safety signal detection. AI-enabled platforms can analyze genomics, pathology images, radiology scans, electronic health records, and real-world datasets to identify responder populations and refine trial design for cancer therapeutics.

The cumulative impact is strongest when AI is integrated with validated clinical evidence, regulatory-grade data governance, and oncology domain expertise. Industry adoption can shorten development cycles, improve patient stratification, support adaptive trials, strengthen pharmacovigilance, and optimize treatment sequencing while requiring careful oversight for bias, explainability, cybersecurity, transparency, and data privacy.

Key Regional Insights Across Global Cancer Drug Demand

Asia-Pacific is a major growth engine for cancer drugs due to large patient populations, expanding oncology infrastructure, and rising adoption of targeted therapies in China, Japan, India, South Korea, and Australia. IARC data show Asia accounts for the largest global cancer burden by new cases, making diagnostics expansion, affordability, and local manufacturing central to oncology access. North America remains the leading innovation hub, supported by high oncology R&D spending, FDA expedited programs, broad biomarker testing, clinical trial activity, and early uptake of immunotherapy, targeted therapy, and cell therapy.

Europe benefits from established reimbursement systems, EMA regulatory pathways, cancer screening programs, and strong clinical research networks, although access varies by country after health technology assessment review. Latin America is expanding access through public procurement, biosimilar adoption, and private oncology networks, while the Middle East is investing in specialized cancer centers, genomic medicine, and national cancer strategies. Africa faces persistent gaps in diagnosis, radiotherapy, pathology, and access to essential oncology medicines, but cancer control initiatives, diagnostics expansion, and international partnerships are improving treatment availability.

Key Group Insights for Oncology Therapeutics

ASEAN cancer drug demand is rising as member states expand universal health coverage, oncology diagnostics, pathology capacity, and hospital-based cancer care, although affordability and reimbursement remain uneven across public and private systems. GCC markets are advancing rapidly through national cancer strategies, specialty hospitals, screening initiatives, and procurement of innovative oncology therapeutics, particularly as regional health systems prioritize precision medicine and high-acuity cancer care.

The European Union is shaped by centralized EMA approvals, joint clinical assessment momentum under health technology assessment reforms, cross-border pharmacovigilance, and policy attention to equitable access to cancer medicines. BRICS countries combine large treatment-naive populations with local manufacturing, generic oncology drugs, biosimilar expansion, and expanding clinical research capacity, while G7 countries lead in high-value innovation, regulatory maturity, clinical trial density, biomarker testing, and premium oncology access. NATO member markets overlap significantly with advanced Western healthcare systems, where supply chain resilience, medicine security, and strategic procurement are increasingly important for oncology therapeutics.

Key Country Insights in the Cancer Drugs Market

The United States anchors global cancer drug innovation through FDA oncology approvals, NCI-backed research, major biopharma investment, broad guideline adoption, and strong uptake of immuno-oncology, targeted therapy, antibody-drug conjugates, and cell therapy. Canada emphasizes evidence-based reimbursement and pan-Canadian oncology evaluation, Mexico is expanding specialty access through institutional and private channels, and Brazil remains Latin America’s most influential oncology environment with rising biosimilar participation, public procurement, and private cancer care networks.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major cancer drug markets with strong clinical expertise, national treatment guidelines, and health technology assessment processes, while Russia maintains demand for essential and locally produced oncology medicines. China is scaling domestic oncology innovation, regulatory reform, clinical trial activity, and access to targeted therapies; India is driven by affordability, generic oncology drugs, biosimilars, and expanding cancer hospital networks; Japan remains a leader in precision treatment, gastric cancer research, and advanced reimbursement pathways; Australia supports high-quality reimbursement and clinical trial infrastructure; and South Korea is expanding biopharma-led oncology R&D, biosimilars, and precision oncology adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated oncology assets with validated biomarkers, clear survival endpoints, manageable safety profiles, and strong evidence for earlier-line, maintenance, adjuvant, neoadjuvant, or combination use. Investment in companion diagnostics, decentralized trial capabilities, adaptive study designs, and diverse patient recruitment can improve regulatory outcomes and strengthen market access dossiers.

Companies should also build payer-ready evidence plans before pivotal trials, including real-world evidence, health economics, patient-reported outcomes, and quality-of-life measures. Strategic partnerships with AI platforms, diagnostics developers, academic cancer centers, contract research networks, manufacturing partners, and regional distributors can accelerate innovation while improving affordability and access in emerging oncology markets.

Research Methodology

This executive summary is developed using secondary research from authoritative public sources, including WHO/IARC cancer burden data, FDA and EMA regulatory information, national cancer agencies, peer-reviewed oncology literature, clinical trial registries, treatment guidelines, pharmacovigilance resources, and health technology assessment publications. Market interpretation is aligned with observable drug approval trends, treatment guideline evolution, biomarker adoption, and regional healthcare access indicators.

The methodology emphasizes triangulation across epidemiology, pipeline activity, regulatory approvals, reimbursement patterns, clinical evidence standards, access dynamics, and competitive intelligence without relying on market sizing or forecasting. Insights are reviewed for relevance to cancer drugs, oncology therapeutics, immunotherapy, targeted therapy, chemotherapy, hormone therapy, radiopharmaceuticals, biosimilars, and precision medicine to support decision-useful analysis.

Conclusion

The cancer drugs market is entering a more precise, data-driven, and outcome-focused era. Rising cancer prevalence, biomarker adoption, immunotherapy expansion, and advanced modalities such as ADCs, bispecific antibodies, radioligand therapies, targeted protein degraders, and cell therapies are redefining competitive advantage across oncology therapeutics.

Future performance will depend on clinical differentiation, affordability, regulatory agility, manufacturing reliability, and evidence generation across diverse populations. Organizations that combine scientific innovation with access strategy, AI-enabled development, diagnostic integration, and regional execution will be best positioned to lead the global oncology therapeutics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Drugs Market, by Drug Type
7.1. Introduction
7.2. Chemotherapy
7.2.1. Alkylating Agents
7.2.2. Antimetabolites
7.2.3. Antitumor Antibiotics
7.3. Hormone Therapy
7.4. Immunotherapy
7.5. Targeted Therapy
7.5.1. Apoptosis-inducing Drugs
7.5.2. Monoclonal Antibodies
7.5.3. Tyrosine Kinase Inhibitors (TKIs)
8. Cancer Drugs Market, by Administration Route
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous
8.4. Oral
8.5. Subcutaneous
9. Cancer Drugs Market, by Therapy Type
9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy
10. Cancer Drugs Market, by Cancer Type
10.1. Introduction
10.2. Breast Cancer
10.3. Colorectal Cancer
10.4. Liver Cancer
10.5. Lung Cancer
10.6. Pancreatic Cancer
10.7. Prostate Cancer
11. Cancer Drugs Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Home Healthcare
11.4. Hospitals & Clinics
12. Cancer Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Retail Pharmacy
13. Cancer Drugs Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Cancer Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Cancer Drugs Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Italy
15.9. Brazil
15.10. Canada
15.11. Mexico
15.12. Russia
15.13. Spain
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. Astellas Pharma Inc
17.4. AstraZeneca PLC
17.5. Bayer AG
17.6. BeiGene, Ltd.
17.7. Bristol-Myers Squibb Company
17.8. Daiichi Sankyo Company, Limited
17.9. Dr. Reddy’s Laboratories Ltd.
17.10. Eli Lilly and Company
17.11. F. Hoffmann-La Roche Ltd
17.12. Fresenius Kabi AG
17.13. Getwell Oncology Pvt Ltd
17.14. GlaxoSmithKline plc
17.15. Incyte Corporation
17.16. Kite Pharma, Inc by Gilead Company
17.17. Medivir AB
17.18. Merck & Co., Inc.
17.19. Nammi Therapeutics, Inc.
17.20. Novartis AG
17.21. Pfizer Inc.
17.22. Sanofi S.A.
17.23. Sun Pharmaceutical Industries Ltd.
17.24. Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
17.25. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTITUMOR ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTITUMOR ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTITUMOR ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HORMONE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HORMONE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL APOPTOSIS-INDUCING DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL APOPTOSIS-INDUCING DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL APOPTOSIS-INDUCING DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TYROSINE KINASE INHIBITORS (TKIS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PANCREATIC CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PANCREATIC CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PANCREATIC CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 118. EUROPE CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. EUROPE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 120. EUROPE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 121. EUROPE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 122. EUROPE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 123. EUROPE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 124. EUROPE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 125. EUROPE CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. EUROPE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. AFRICA CANCER DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 138. AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 139. AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 140. AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 141. AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 142. AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 143. AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. ASEAN CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. ASEAN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 148. ASEAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 149. ASEAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 150. ASEAN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 151. ASEAN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 152. ASEAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 153. ASEAN CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. ASEAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 155. GCC CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. GCC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 157. GCC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 158. GCC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 159. GCC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 160. GCC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 161. GCC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 162. GCC CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. GCC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 173. BRICS CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. BRICS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 175. BRICS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 176. BRICS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 177. BRICS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 178. BRICS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 179. BRICS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 180. BRICS CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. BRICS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. G7 CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. G7 CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 184. G7 CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 185. G7 CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 186. G7 CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 187. G7 CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 188. G7 CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 189. G7 CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. G7 CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. NATO CANCER DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. NATO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 193. NATO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 194. NATO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 195. NATO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 196. NATO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 197. NATO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 198. NATO CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. NATO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 210. CHINA CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 211. CHINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 212. CHINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 213. CHINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 214. CHINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 215. CHINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 216. CHINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 217. CHINA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. CHINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 219. GERMANY CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. GERMANY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 221. GERMANY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 222. GERMANY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 223. GERMANY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 224. GERMANY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 225. GERMANY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 226. GERMANY CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. GERMANY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. JAPAN CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 229. JAPAN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 230. JAPAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 231. JAPAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 232. JAPAN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 233. JAPAN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 234. JAPAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 235. JAPAN CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. JAPAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. INDIA CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. INDIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 239. INDIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 240. INDIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 241. INDIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 242. INDIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 243. INDIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 244. INDIA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 245. INDIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. FRANCE CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. FRANCE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 257. FRANCE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 258. FRANCE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 259. FRANCE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 260. FRANCE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 261. FRANCE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 262. FRANCE CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. FRANCE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. ITALY CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. ITALY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 266. ITALY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 267. ITALY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 268. ITALY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 269. ITALY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 270. ITALY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 271. ITALY CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 272. ITALY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 278. BRAZIL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 279. BRAZIL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 280. BRAZIL CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. BRAZIL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 282. CANADA CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. CANADA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 284. CANADA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 285. CANADA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 286. CANADA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 287. CANADA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 288. CANADA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 289. CANADA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. CANADA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 291. MEXICO CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. MEXICO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 293. MEXICO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 294. MEXICO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 295. MEXICO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 296. MEXICO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 297. MEXICO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 298. MEXICO CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. MEXICO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 300. RUSSIA CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. RUSSIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 302. RUSSIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 303. RUSSIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 306. RUSSIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 307. RUSSIA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. SPAIN CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. SPAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 311. SPAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 312. SPAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 313. SPAIN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 314. SPAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 315. SPAIN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 316. SPAIN CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. SPAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 318. AUSTRALIA CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. AUSTRALIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 320. AUSTRALIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 321. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 322. AUSTRALIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 323. AUSTRALIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 324. AUSTRALIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 325. AUSTRALIA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. AUSTRALIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 327. SOUTH KOREA CANCER DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 328. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 329. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 330. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 331. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2017-2032 (USD MILLION)
TABLE 332. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 333. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 334. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 335. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 336. GLOBAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 337. GLOBAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol‑Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Kite Pharma, Inc by Gilead Company
  • Medivir AB
  • Merck & Co., Inc.
  • Nammi Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 188.72 Billion
Forecasted Market Value ( USD ) by 2032 $ 338.29 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Image

United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • 80 Pages
  • United States
From
North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030 - Product Image

North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

  • Report
  • 151 Pages
  • North America
From
Software as a Medical Device (SaMD) for Oncology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Software as a Medical Device (SaMD) for Oncology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 150 Pages
  • Global
From
Gastric Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Gastric Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Gynecological Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Gynecological Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From

About the Oncology Drugs Market

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.